Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Ono President Professes High Hopes for Newly Approved Anticancer Drug Opdivo
July 16, 2014
- Antiepileptic Treatment Aptiom Approved in Canada: Sumitomo Dainippon
July 16, 2014
- Astellas Files Irribow for Diarrhea-Predominant Irritable Bowel Syndrome in Females
July 16, 2014
- Ex-Astellas Chair Sounds Alarm over Oncology-Focused Businesses, Says Govt Finances Will Be Insufficient
July 15, 2014
- Kyowa Kirin’s UK Subsidiary Acquires Archimedes
July 15, 2014
- Otsuka Files NDA for Abilify Successor Drug Brexpiprazole in US
July 15, 2014
- “Favorable Transactions” for Nesp in Return for Support in Clinical Trial: Independent Panel
July 14, 2014
- Astellas, IBL to Study Manufacturing Method for Agent Utilizing Human Fibrinogen
July 14, 2014
- Takata Seiyaku Looks to Sales of 30 Billion Plus Yen by 2016
July 11, 2014
- Astellas Gearing Up to Expand Xtandi Indication Globally: Chief Medical Officer
July 11, 2014
- Astellas Selects Anticancer FLT3/AXL Inhibitor for Fast-Track Development
July 11, 2014
- Nippon Chemiphar Receives Approval for Actos Generic in Hong Kong: President
July 11, 2014
- Ono to Provide University of Tokyo with Access to Its Compound Library
July 11, 2014
- Bayer Yakuhin Adopts Unique Certificate Program to Train Cancer Sales Reps
July 10, 2014
- Novartis Lays Out New Global Guidelines for Investigator-Led Trials
July 10, 2014
- LSI Medience Develops Cardiotoxicity Assessment System Using Myocardial iPS Cells in NEDO-Driven Research Project
July 10, 2014
- Apeiron Begins PI Study of Neuroblastoma Immunotherapy Agent in Japan
July 10, 2014
- Vital-Net Makes Miyagi-Based Dispensing Pharmacy Chain Ohno its Subsidiary
July 10, 2014
- Bayer Yakuhin Sees Cancer Drugs as New Pillar
July 9, 2014
- MTPC to Up Japan Sales Force by 200-300 Partly via Job Transfers
July 9, 2014
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…